VA Study of 68,881 Veterans Starting NSAIDs Finds No Higher Stomach-Bleeding Risk on GLP-1 Drugs Than on SGLT2 or DPP-4 Inhibitors
Iowa City VA researchers followed veterans with type 2 diabetes who started a nonsteroidal anti-inflammatory drug while already taking a GLP-1 drug (13,433), an SGLT2 inhibitor (24,480), or a DPP-4 inhibitor (30,968). A GI bleed or ulcer within 12 months occurred in 0.9%, 1.0%, and 1.0%, and adjusted hazard ratios for GLP-1 users were 0.85 versus SGLT2 inhibitors and 0.82 versus DPP-4 inhibitors, neither statistically significant. The observational study appears in the American Journal of Health-System Pharmacy.